½ÃÀ庸°í¼­
»óǰÄÚµå
1388275

¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ½ÃÀå : À¯Çüº°, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2023-2032³â)

Preventive Healthcare Technologies and Services Market - By Type (Early Detection and Screening, Chronic Disease Management Technologies, Vaccines, Advanced Technologies to Reduce Errors), End-use (Hospital, Clinics)- Global Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ½ÃÀå ±Ô¸ð´Â ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Çコ Ç÷§ÆûÀÇ ¼¼°è º¸±Þ¿¡ ÀÇÇØ ÃËÁøµÇ¸ç, 2023-2032³â CAGR 10.3%·Î È®´ëÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¿ø°ÝÀÇ·á ¹× µðÁöÅÐ °Ç°­ ±â¼úÀº ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¿ø°Ý ¾×¼¼½º¸¦ ¿ëÀÌÇÏ°Ô ÇÏ°í ¿¹¹æÀû ÇコÄÉ¾î ¹× ¿¹¹æ Ä¡·á¸¦ °­È­ÇÕ´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á Ç÷§ÆûÀº °¡»ó Áø·á, °Ç°­ ¸ð´ÏÅ͸µ ¹× °³ÀÎÈ­µÈ À£´Ï½º Ç÷£À» Á¦°øÇÏ¿© ÆíÀǼº°ú Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.

¶ÇÇÑ ¿©·¯ ¾÷°è °ü°èÀÚµéÀº ÇöÀç ¾Ï, °ü»óµ¿¸ÆÁúȯ, ½Å°æÅðÇ༺ Áúȯ µî ÀáÀçÀû Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â Á¤¹Ð Áø´Ü °Ë»ç¿Í ÇÔ²² ÷´Ü ±â¼ú °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â »ê¾÷ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÏ·Ê·Î, µðÁöÅÐ ÇコÄÉ¾î ±â¾÷ À£ Çコ Å×Å©³î·¯Áö½º(Well Health Technologies Corp.)´Â 2023³â 11¿ù °³Àΰú ±â¾÷ÀÇ À£ºùÀÇ ¹Ì·¡¸¦ ÀçÁ¤ÀÇÇϱâ À§ÇØ ¿¹¹æ ÀÇ·á ºÎ¹®ÀÇ Ã·´Ü È®Àå ÇÁ·Î±×·¥ÀÎ 'À£ Àå¼ö ÇÁ·Î±×·¥(WELL Longevity Program)'À» ¹ßÇ¥Çß½À´Ï´Ù.

¿¹¹æÀÇ·á ±â¼ú ¹× ¼­ºñ½º »ê¾÷Àº À¯Çü, ÃÖÁ¾ ¿ëµµ, Áö¿ªº°·Î ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î º¸¸é ¹é½Å ºÐ¾ß ½ÃÀå ±Ô¸ð´Â ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ Á߿伺ÀÌ ºÎ°¢µÇ¸é¼­ 2023-2032³â 10.4%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â Çõ½ÅÀûÀÎ ¹é½Å Àü´Þ ½Ã½ºÅÛ, º¸°ü ¼Ö·ç¼Ç, À¯Åë ³×Æ®¿öÅ©¿¡ ÅõÀÚÇÏ¿© Á¢±Ù¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ COVID-19 ÆÒµ¥¹Í ÀÌÈÄ °¨¿°º´ ¿¹¹æÁ¢Á¾¿¡ ´ëÇÑ ¼¼°èÀÇ °ü½ÉÀÌ ³ô¾ÆÁø °Íµµ ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµº°·Î´Â Ŭ¸®´Ð ºÐ¾ßÀÇ ¿¹¹æ ÀÇ·á ±â¼ú ¹× ¼­ºñ½º »ê¾÷ÀÌ 2023-2032³â 10.4%ÀÇ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº Æí¸®Çϰí Á¾ÇÕÀûÀÎ ÇコÄɾ ¿øÇÏ´Â °í°´ Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Ç¥ÀûÈ­µÈ ÁßÀç ¹× Á¶±â ¹ß°ß ¼­ºñ½º¸¦ Á¦°øÇϴ Ŭ¸®´ÐÀÇ ÀαⰡ ³ô¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ Å¬¸®´ÐÀº »çÀü ¿¹¹æÀû ÇコÄÉ¾î ¼­ºñ½º¸¦ Á¦°øÇϱâ À§ÇØ °Ç°­ °ËÁø, À¯ÀüÀÚ °Ë»ç, µ¥ÀÌÅÍ ºÐ¼®°ú °°Àº ÷´Ü ±â¼úÀ» äÅÃÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¹¹æ ÀÇ·áÀÇ ÀÌÁ¡¿¡ ´ëÇÑ °³ÀÎÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÌ ºÐ¾ß°¡ È®´ëµÇ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿¹¹æ ÀÇ·á ±â¼ú ¹× ¼­ºñ½º ½ÃÀåÀº 2032³â±îÁö °ß°íÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄÉ¾î ºñ¿ëÀÇ »ó½Â°ú °í·ÉÈ­ Àα¸ Áõ°¡·Î ÀÎÇØ ÀÌ Áö¿ª Á¤ºÎ¿Í °³ÀεéÀÌ ¿¹¹æÀû Á¶Ä¡¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÏ·Ê·Î ¾Èµå¶óÇÁ¶óµ¥½Ã ÁÖ Á¤ºÎ´Â 2023³â 9¿ù ¾Ï Ä¡·á ¹× Åõ¼® ȯÀÚ¸¦ Æ÷ÇÔÇÑ 7°¡Áö Áø´Ü °Ë»ç·Î ±¸¼ºµÈ »õ·Î¿î ¿¹¹æ ÀÇ·á ÇÁ·Î±×·¥ÀÎ 'Jagananna Aarogya Suraksha'¸¦ ½ÃÀÛÇß½À´Ï´Ù. ¶ÇÇÑ ¿þ¾î·¯ºí ±â±â, ¿ø°ÝÀÇ·á, °Ç°­ ¸ð´ÏÅ͸µ ¾Û µî ÷´Ü ±â¼úÀÇ º¸±Þµµ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ °³ÀÎ ¸ÂÃãÇü ¿ø°ÝÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ¾÷°è ÀλçÀÌÆ®

  • COVID-19 ¿µÇ⠺м®
  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ±â¼ú »óȲ
  • ±ÔÁ¦ »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯÀÇ ºÎ´ã Áõ°¡
      • µðÁöÅÐ ÇコÄÉ¾î ±â¼úÀÇ Ã¤Åà Áõ°¡
      • Á¤ºÎ¿¡ ÀÇÇÑ °è¹ß ÇÁ·Î±×·¥ÀÇ Áõ°¡
      • ¿¹¹æ ÇコÄÉ¾î ±â¼úÀÇ Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ÇコÄɾî IT Àü¹®°¡ÀÇ ºÎÁ·
      • ¾ö°ÝÇÑ ±ÔÁ¦ ½Ã³ª¸®¿À
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
    • GlaxoSmithKline
    • Abbott Laboratories
    • Merck & Co. Inc
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • Á¶±â ¹ß°ß°ú ½ºÅ©¸®´×
    • ÀÚµ¿ ½ºÅ©¸®´×
    • ¸ÂÃãÇü ÀÇ·á
    • ±âŸ ÷´Ü ½ºÅ©¸®´× ±â¼ú
  • ¸¸¼ºÁúȯ °ü¸® ±â¼ú
    • Ç÷¾Ð ¸ð´ÏÅÍ
    • õ½Ä ¸ð´ÏÅÍ
    • ½ÉÇ÷°ü ¸ð´ÏÅÍ
    • ±Û·çÄÚ¿À½º ¸ð´ÏÅÍ
  • ¹é½Å
    • °¨¿°Áõ
    • ÆÄ»ódz¡¤µðÇÁÅ׸®¾Æ¡¤¹éÀÏÇØ È¥ÇÕ¹é½Å
    • ¾Ë·¹¸£±â
    • ±âŸ
  • ¿¡·¯ »è°¨À» À§ÇÑ Ã·´Ü ±â¼ú
    • ÀüÀÚó¹æ
    • ÀÓ»ó ÆÇ´Ü Áö¿ø ½Ã½ºÅÛ
    • ½º¸¶Æ® ÁÖÀÔ ÆßÇÁ
    • CPOE(Computerized provider order entry) ½Ã½ºÅÛ
    • ½º¸¶Æ® Æ÷Àå
    • ÀÚµ¿ 󹿡¤Á¶Á¦

Á¦6Àå ¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾ ¿ëµµº°
  • º´¿ø
  • Áø·á¼Ò
  • ±âŸ ÃÖÁ¾ ¿ëµµ

Á¦7Àå ¿¹¹æ ÇコÄÉ¾î ±â¼ú°ú ¼­ºñ½º ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ±â¾÷ °³¿ä

  • GlaxoSmithKline
  • Omnicell, Inc
  • Myriad Genetics
  • Omron Healthcare
  • Abbott Laboratories
  • Medtronic
  • Quest Diagnostics
  • Merck & Co. Inc.
  • Sanofi
  • NOVX Systems Corp
  • Moderna, Inc
  • Pfizer
  • Teladoc Health
  • McKesson Corporation
  • Practice Fusion Inc
KSA 23.12.13

Preventive Healthcare Technologies and Services Market size is estimated to expand at 10.3% CAGR from 2023-2032, driven by the widespread adoption of telemedicine and digital health platforms across the globe. Telemedicine and digital health technologies facilitate remote access to healthcare services to offer enhanced proactive health management and preventive care. Additionally, telemedicine platforms offer virtual consultations, health monitoring, and personalized wellness plans for promoting convenience and accessibility.

Moreover, multiple industry participants are currently focusing on developing cutting-edge technologies along with precision diagnostic testing for early detection of potential conditions, such as cancer, coronary artery disease, and neurodegenerative diseases, boosting the industry growth. To cite an instance, in November 2023, WELL Health Technologies Corp., a digital healthcare company, introduced a progressive extension for its preventative health division, the WELL Longevity+ Program to redefine the future of personal and corporate wellness.

The preventive healthcare technologies and services industry is segmented into type, end-use, and region.

Based on type, the market size from the vaccines segment is anticipated to record 10.4% CAGR from 2023-2032 owing to the increasing emphasis on immunization as critical preventive measures. Governments and healthcare providers are investing in innovative vaccine delivery systems, storage solutions, and distribution networks to enhance accessibility. In addition, the rising global focus on vaccination against infectious diseases since the onset of the COVID-19 pandemic is fuelling the segment growth.

In terms of end-use, the preventive healthcare technologies and services industry from the clinics segment is projected to witness 10.4% rate between 2023 and 2032. The growth can be attributed to the rising popularity of clinics for delivering targeted interventions and early detection services to cater to the growing clientele seeking convenient and comprehensive healthcare. Furthermore, clinics are increasingly adopting advanced technologies, such as health screenings, genetic testing, and data analytics to offer proactive health management services. The rising awareness among individuals about the benefits of preventive care will also contribute to the segment expansion.

Regionally, the Asia Pacific preventive healthcare technologies and services market is estimated to depict a robust growth rate through 2032. Rising healthcare costs and the expanding aging population are propelling governments and individuals in the region to invest in preventive measures. To cite an instance, in September 2023, the government of Andhra Pradesh launched a new preventive healthcare program, Jagananna Aarogya Suraksha comprising seven different kinds of diagnostic tests on patients, including those receiving cancer treatment and dialysis. Moreover, the proliferation of advanced technologies, such as wearable devices, telehealth, and health monitoring apps is also fostering the demand for personalized and remote healthcare services across the APAC.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global preventive healthcare technologies and services market 360 degree synopsis, 2018 - 2032
  • 2.2 Regional trends
  • 2.3 Type trends
  • 2.4 End-use trends

Chapter 3 Preventive Healthcare Technologies and Services Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Growing burden of chronic diseases
      • 3.5.1.2 Increasing adoption of digital healthcare technology
      • 3.5.1.3 Growing number of awareness programs by the government.
      • 3.5.1.4 Advancement in preventive healthcare technology
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 Lack of healthcare IT professionals
      • 3.5.2.2 Stringent regulatory scenario
  • 3.6 Growth potential analysis
    • 3.6.1 By type
    • 3.6.2 By end-use
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
    • 4.1.1 GlaxoSmithKline
    • 4.1.2 Abbott Laboratories
    • 4.1.3 Merck & Co. Inc
  • 4.2 Competitive analysis of major market players, 2022
  • 4.3 Competitive positioning matrix, 2022
  • 4.4 Strategic outlook matrix, 2022

Chapter 5 Preventive Healthcare Technologies and Services Market Size and Forecast, By Type, 2018-2032 (USD Million)

  • 5.1 Key trends, by type
  • 5.2 Early detection and screening
    • 5.2.1 Automated screening
    • 5.2.2 Personalized medicine
    • 5.2.3 Other advanced screening technologies
  • 5.3 Chronic disease management technologies
    • 5.3.1 Blood pressure monitors
    • 5.3.2 Asthma monitors
    • 5.3.3 Cardiovascular monitors
    • 5.3.4 Glucose monitors
  • 5.4 Vaccines
    • 5.4.1 Infectious diseases
    • 5.4.2 Combined tetanus-diphtheria-pertussis vaccines
    • 5.4.3 Allergy
    • 5.4.4 Others
  • 5.5 Advanced technologies to reduce errors
    • 5.5.1 Electronic prescribing
    • 5.5.2 Clinical decision support system
    • 5.5.3 Smart infusion pumps
    • 5.5.4 Computerized provider order entry system
    • 5.5.5 Smart packaging
    • 5.5.6 Automated prescription formulation & dispensing

Chapter 6 Preventive Healthcare Technologies and Services Market Size and Forecast, By End-use, 2018-2032 (USD Million)

  • 6.1 Key trends, by end-use
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Other end-users

Chapter 7 Preventive Healthcare Technologies and Services Market Size and Forecast, By Region, 2018-2032 (USD Million)

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East & Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East & Africa

Chapter 8 Company Profiles

  • 8.1 GlaxoSmithKline
  • 8.2 Omnicell, Inc
  • 8.3 Myriad Genetics
  • 8.4 Omron Healthcare
  • 8.5 Abbott Laboratories
  • 8.6 Medtronic
  • 8.7 Quest Diagnostics
  • 8.8 Merck & Co. Inc.
  • 8.9 Sanofi
  • 8.10 NOVX Systems Corp
  • 8.11 Moderna, Inc
  • 8.12 Pfizer
  • 8.13 Teladoc Health
  • 8.14 McKesson Corporation
  • 8.15 Practice Fusion Inc
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦